Juliana M Bue-Valleskey (Juliana Bue-Valleskey)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 6

Top Topics

Randomized Controlled Trial

Glycemic Control

Top Venues

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Richard M Bergenstal, Athena Philis-Tsimikas, Carol H Wysham, Molly C Carr, Juliana M Bue-Valleskey, Fady T Botros, Thomas Blevins, Julio Rosenstock
Once-weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme. Diabetes, obesity & metabolism 26 (8) (2024)
Richard M Bergenstal, Athena Philis-Tsimikas, Carol H Wysham, Molly C Carr, Juliana M Bue-Valleskey, Fady T Botros, Thomas Blevins, Julio Rosenstock
Once-weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme. Diabetes, obesity & metabolism (2024)
Juliana M Bue-Valleskey, Christof M Kazda, Chenchen Ma, Jenny Chien, Qianyi Zhang, Emmanuel Chigutsa, William Landschulz, Axel Haupt, Juan P Frias
Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial. Diabetes care (2023)
Christof M Kazda, Juliana M Bue-Valleskey, Jenny Chien, Qianyi Zhang, Emmanuel Chigutsa, William Landschulz, Paula Wullenweber, Axel Haupt, Dominik Dahl
Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes. Diabetes care (2023)
Tim Heise, Helle Linnebjerg, David Coutant, Elizabeth LaBell, Eric Zijlstra, Christoph Kapitza, Juliana M Bue-Valleskey, Qianyi Zhang, Mary Anne Dellva, Jennifer Leohr
Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. Diabetes, obesity & metabolism 22 (10) (2020)
Leslie Klaff, Dachuang Cao, Mary Anne Dellva, Janet Tobian, Junnosuke Miura, Dominik Dahl, Jean Lucas, Juliana M Bue-Valleskey
Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26-week PRONTO-T1D study. Diabetes, obesity & metabolism 22 (10) (2020)